Everything below concerns Nicotinamide mononucleotide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C11H15N2O8P | Identifies the atoms in the nucleotide |
| Molar mass | 334.22 g/mol | Calculated from the molecular formula |
| Appearance | White to off-white powder | Typical for purified solid material |
| Solubility | Water-soluble | Polar nucleotide; less soluble in nonpolar solvents |
| Common synonyms | Nicotinamide mononucleotide; beta-NMN | beta-NMN refers to the common anomeric form |
The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.
Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure consists of a nicotinamide ring linked to ribose phosphate, and the compound serves as an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+. In this pathway, nicotinamide phosphoribosyltransferase converts nicotinamide and phosphoribosyl pyrophosphate into NMN, after which NMN adenylyltransferase attaches an adenylate group to produce NAD+. Because NAD+ participates in redox reactions and signaling, NMN occupies a central position in cellular metabolism. The molecule is distinct from nicotinamide riboside, though the two are related in NAD+ precursor research.
Beyond its intracellular synthesis, NMN can be taken up from the extracellular environment, although the routes are still debated. Some evidence points to direct transport into cells through specific transporters, while other work suggests dephosphorylation to nicotinamide riboside followed by cellular uptake. Once inside, NMN can be converted to NAD+ by NMN adenylyltransferases; the relative contribution of these routes may differ by tissue, species, and experimental conditions. Researchers continue to investigate which mechanisms dominate in intact organisms and how they affect measured NAD+ levels. Direct measurement in tissues remains technically challenging because NMN can be rapidly metabolized during sample collection.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
Auxotrophy (Ancient Greek: αὐξάνω "to increase"; τροφή "nourishment") is the inability of an organism to synthesize a particular organic compound required for its growth (as defined by IUPAC). An auxotroph is an organism that displays this characteristic; auxotrophic is the corresponding adjective. Auxotrophy is the opposite of prototrophy, which is characterized by the ability to synthesize all the compounds needed for growth. Prototrophic cells are self-sufficient producers of all required metabolites (e.g. amino acids, lipids, cofactors), while auxotrophs require to be on medium with the metabolite that they cannot produce. For example, a methionine auxotrophic cell could only grow on a medium that contained methionine; otherwise, it would starve. In this example, this is because it is unable to produce its own methionine. However, a methionine prototrophic cell would be able to function and replicate on a medium with or without methionine. Replica plating is a technique that transfers colonies from one plate to another in the same spot as the last plate so the different media plates can be compared side by side. It is used to compare the growth of the same colonies on different plates of media to determine which environments the bacterial colony can or cannot grow in (this gives insight to possible auxotrophic characteristics). The method of replica plating implemented by Joshua Lederberg and Esther Lederberg included auxotrophs that were temperature-sensitive; that is, their ability to synthesize was temperature-dependent.
This was announced after the BBC had experimented with 8K during the London Olympics. On January 27, 2013, Asahi Shimbun reported that 4K Ultra HD satellite broadcasts would start in Japan with the 2014 FIFA World Cup. Japan's Ministry of Internal Affairs and Communications decided on this move to stimulate demand for 4K Ultra HD TVs. On February 21, 2013, Sony announced that the PlayStation 4 would support 4K resolution output for photos and videos but wouldn't render games at that resolution. On March 26, 2013, the Advanced Television Systems Committee (ATSC) announced a call for proposals for the ATSC 3.0 physical layer that specifies support for 3840 × 2160 resolution at 60 fps. On 11 April 2013, Bulb TV created by Canadian entrepreneur Evan Kosiner announced a 4K linear channel and VOD content to cable and satellite companies in North America. The channel planned to be licensed by the Canadian Radio-Television and Telecommunications Commission to provide educational content. On April 19, 2013, SES announced the first Ultra HD transmission using the High Efficiency Video Coding(HEVC) standard. The transmission had a resolution of 3840 × 2160 and a bit rate of 20 Mbit/s. On May 9, 2013, NHK and Mitsubishi Electric announced that they had jointly developed the first HEVC encoder for 8K Ultra HD TV, which is also called Super Hi-Vision (SHV). The HEVC encoder supports the Main 10 profile at Level 6.1 allowing it to encode 10 bpc video with a resolution of 7680 × 4320 at 60 fps.
== Function == BMPs interact with specific receptors on the cell surface, referred to as bone morphogenetic protein receptors (BMPRs). Signal transduction through BMPRs results in mobilization of members of the SMAD family of proteins. The signaling pathways involving BMPs, BMPRs and SMADs are important in the development of the heart, central nervous system, and cartilage, as well as post-natal bone development. They have an important role during embryonic development on the embryonic patterning and early skeletal formation. As such, disruption of BMP signaling can affect the body plan of the developing embryo. For example, BMP4 and its inhibitors noggin and chordin help regulate polarity of the embryo (i.e. back to front patterning). Specifically BMP-4 and its inhibitors play a major role in neurulation and the development of the neural plate. BMP-4 signals ectoderm cells to develop into skin cells, but the secretion of inhibitors by the underlying mesoderm blocks the action of BMP-4 to allow the ectoderm to continue on its normal course of neural cell development. Additionally, secretion of BMPs by the roof plate in the developing spinal cord helps to specify dorsal sensory interneurons. As a member of the transforming growth factor-beta superfamily, BMP signaling regulates a variety of embryonic patterning during fetal and embryonic development. For example, BMP signaling controls the early formation of the Müllerian duct (MD) which is a tubular structure in early embryonic developmental stage and eventually becomes female reproductive tracts.
== Strategic partnerships == As a major developer and manufacturer in the international drug market, Biocon maintains partnerships with many corporations in the global pharmaceutical market. In 2004, Biocon is began developing human antibodies BVX 10 and BVX-20 with US antibody producer, Vaccinex. BVX 10 targets TNF (Tumor Necrosis Factor) which is expressed at high levels in patients with rheumatoid arthritis. In 2007, Biocon and Abraxis BioScience, Inc. entered into an agreement that helped Biocon out-license the rights to develop and market a biosimilar version of GCSF (Granulocyte Colony-Stimulating Factor) to North American and European markets. In 2008, Biocon and IATRICa announced a partnership to co-develop immunoconjugates for targeted immunotherapy of cancers and infectious diseases, in particular T cell-mediated immunotherapy. In 2009, Biocon and Amylin Pharmaceuticals of the United States entered into an agreement to develop, commercialise and manufacture a novel peptide therapeutic for the potential treatment of diabetes. The same year, Biocon signed a collaboration agreement with Viatris to develop and commercialize generic biologics, with Viatris maintaining exclusive commercialisation rights in the US, Canada, Japan, Australia, New Zealand, EU, and European Free Trade Association countries through a profit-sharing arrangement. In January 2018, Sandoz (a Novartis division) announced a global partnership with Biocon to develop, manufacture, and commercialize multiple biosimilars in immunology and oncology for patients worldwide.
=== Choanoflagellates === Choanoflagellates, also called "collar-flagellates," are unicellular organisms that exist in both freshwater and oceans. Choanoflagellates have a spherical or ovoid cell body and a flagellum that is surrounded by a 'collar' composed of actin microvilli. The flagellum is used to facilitate movement and food intake. As the flagellum beats, it takes in water through the microvilli attached to the collar, which helps filter out unwanted bacteria and other tiny food particles. Choanoflagellates are composed of approximately 150 species and reproduce by binary fission.
Sources: en.wikipedia.org
In the case of recreational substance use, harm reduction is put forward as a useful perspective alongside the more conventional approaches of demand and supply reduction. Many advocates argue that prohibitionist laws criminalise people for suffering from a disease and cause harm for example, by obliging people who use substances to obtain substances of unknown purity from unreliable criminal sources at high prices, thereby increasing the risk of overdose and death. The web forum Bluelight allows users to share information and first-hand experience reports about various psychoactive substances and harm reduction practices. The website Erowid collects and publishes information and first-hand experience reports about all kinds of substances to educate people who use or may use substances. While the vast majority of harm reduction initiatives are educational campaigns or facilities that aim to reduce substance-related harm, a unique social enterprise was launched in Denmark in September 2013 to reduce the financial burden of illicit substance use for people with a drug dependence. Michael Lodberg Olsen, who was previously involved with the establishment of a substance consumption facility in Denmark, announced the founding of the Illegal magazine that will be sold by people who use substances in Copenhagen and the district of Vesterbro, who will be able to direct the profits from sales towards drug procurement.
Rindo Azami (阿左美 竜胆, Azami Rindō) Voiced by: Taku Yashiro (Japanese); Lee George (English) The Agent of Autumn's Guard. He treats his job like a business, without letting his emotions get in the way. Those around him don't see it that way. He doesn't realize it, but he's overprotective of Nadeshiko.
== Reception == Cry of Fear has received generally positive reviews, with reviewers praising its overall atmosphere and unique setting. Reviewers praised the game's story, atmosphere, tension, enemy designs, and inventory management, while some criticism was levied at the game's platforming segments and occasional crashes and bugs. Eric Sapp of IGN called the game "terrifying" and praised the addition of an inventory system with limited space similar to Resident Evil series for the decision making aspect. Antony Wright of SUPERJUMP named Cry of Fear "arguably the most disturbing and depraved horror title that I've ever played through" while also commending the game for sympathetically handling mature topics. Dennis Moiseyev and Destry Stutesman of The Gamer positively compared Cry of Fear to the Silent Hill series through its use of nightmare sequences, while employing a first-person perspective. Luke Plunkett of Kotaku opined that while the old engine made the game "a little janky" at times, the graphics and music in Cry of Fear were "genuinely tense". A review on Jeuxvideo.com praised the innovations to the GoldSrc engine, calling the improved the graphics and lighting in Cry of Fear unrecognized to Half-Life. Although acknowledging the technical limitations of an outdated engine, the music and "gloomy atmosphere" were also applauded by Jeuxvideo.com, stating the game proves "that a graphics engine, no matter how old it may be, can do some very beautiful things if it is used well".
Feminizing hormone therapy is typically used by transgender women, who desire the development of feminine secondary sex characteristics. Individuals who identify as non-binary may also opt-in for feminizing hormone treatment to better align their body with their desired gender expression. Feminizing hormone therapy usually includes medication to suppress testosterone production and induce feminization. Types of medications include estrogens, antiandrogens (testosterone blockers), and progestogens. Most commonly, an estrogen is combined with an antiandrogen to suppress and block testosterone. This allows for demasculinization and promotion of feminization and breast development. Estrogens are administered in various modalities including injection, transdermal patch, and oral tablets. The desired effects of feminizing hormone therapy focus on the development of feminine secondary sex characteristics. These desired effects include: breast tissue development, redistribution of body fat, decreased body hair, reduction of muscle mass, and more. The table below summarizes some of the effects of feminizing hormone therapy in transgender women:
Sources: en.wikipedia.org
== Early life and education == Leena Maria Hämäläinen (later Ala-Kokko) was born on 21 July 1961 in Oulu, Finland. She graduated from high school at Oulun Lyseon lukio in 1980. She continued her studies at the University of Oulu, from which she obtained her licentiate in medicine in 1986, before gaining her PhD in medicine the following year. In her thesis, Ala-Kokko studied the overproduction of collagen in the skin and liver. Ala-Kokko gained research experience in professor Kari Kivirikko's collagen research group.
== Further reading == Arnold D (2010). "British India and the beri-beri problem". Medical History. 54 (3): 295–314. doi:10.1017/S0025727300004622. PMC 2889456. PMID 20592882. Chisholm H, ed. (1911). "Beri-Beri" . Encyclopædia Britannica. Vol. 03 (11th ed.). Cambridge University Press. pp. 774–775. Smith HA (2017). Forgotten Disease: Illnesses Transformed in Chinese Medicine. doi:10.1093/jhmas/jry029. ISBN 978-1-5036-0350-9. OCLC 993877848.
Mankiewicz (1942), television and film writer; Academy Award nominee for I Want to Live! Steve Krantz (1943), screenwriter and film producer, Fritz the Cat Ernest Kinoy (1947), television writer of Murrow, Roots, and Victory at Entebbe Merrill Brockway (1948), Emmy Award-winning television producer Saul Turteltaub (1954), Emmy Award-nominated television writer and producer William Kronick (1955), film and television writer, director and producer Stephen Schenkel (1956), TV producer, All My Children Milton Moses Ginsberg (1957), director, Coming Apart Doran William Cannon (1959), screenwriter of Skidoo and Brewster McCloud Richard Pearlman (1959), former director of the Washington National Opera as well as the training program at the Lyric Opera of Chicago Terrence McNally (1960), Tony Award-winning playwright; author of Kiss of the Spider Woman and Ragtime Michael Kahn (1961), artistic director of the Shakespeare Theatre Company in Washington, D.C. Brian De Palma (1962), director of Scarface, The Untouchables and Carrie Crawford Kilian (1962), Canadian novelist and professor at Capilano University Thomas H.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a nucleotide intermediate in the cellular pathway that produces NAD+, a coenzyme involved in energy metabolism and signaling. NMN is not the same compound as NAD+.
NMN is a direct precursor to NAD+ in the salvage pathway. The enzyme NMNAT converts NMN into NAD+ by adding an adenine nucleotide group. This relationship is why NMN is studied in the context of NAD+ decline.
Yes, NMN is produced naturally in cells as part of NAD+ recycling. It also appears in small and variable amounts in some foods. Its natural presence does not by itself establish that supplemental NMN has clinical benefits.
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide intermediate in NAD+ biosynthesis.